Investor Relations

Press Releases

Date Title and Summary
October 5, 2021
Amos Ron to Retire as CFO and Will Continue to Serve as Corporate Secretary, Advisor to VBL TEL AVIV, Israel and NEW YORK , Oct. 05, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT ) today announced the appointment of Sam Backenroth as chief financial officer (CFO) effective immediately.
September 17, 2021
The OVAL Phase 3 clinical trial evaluating VB-111 in platinum-resistant ovarian cancer has recruited more than 320 patients (>80 %) to date; Remains on track to complete enrollment in 1Q22 TEL AVIV, Israel , Sept. 17, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ: VBLT ) today announced that
September 10, 2021
TEL AVIV, Israel , Sept. 10, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics ( NASDAQ: VBLT ) today announced the Company will present in the following upcoming industry conferences: H.C. Wainwright 23rd Annual Global Investment Conference Mon., Sept. 13, 2021 Fireside chat available on-demand beginning
August 30, 2021
U.S. FDA CMC clearance of VB-111 produced in Modiin, Israel facility an important milestone toward potential commercialization OVAL Phase 3 trial evaluating VB-111 in platinum resistant ovarian cancer has recruited nearly 80% of target enrollment; remains on track to complete enrollment in 1Q22
August 16, 2021
Conference Call and Webcast at 8:30 a.m. EDT Today   ●   Closed public offering raising net proceeds of $26.4 million ; cash position is expected to fund operations until year-end 2023, through readout from the OVAL study and potential Biologics License Application (BLA) submission for VB-111 in
August 5, 2021
TEL AVIV, Israel , Aug. 05, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics ( Nasdaq: VBLT ) will release its second quarter financial results for the period ended June 30, 2021 on Monday, August 16 before market open. Professor Dror Harats, M.D, Chief Executive Officer and Amos Ron , Chief Financial
July 22, 2021
TEL AVIV, Israel , July 22, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics ( Nasdaq: VBLT ) today announced the planned elevation of Marc Kozin as chairman of the company’s board of directors. Bennett Shapiro , M.D., has stepped down from his chairman role but remains on VBL’s board.
July 8, 2021
TEL AVIV, Israel , July 08, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced the appointments of Alison Finger and Michael Rice to its Board of Directors, effective July 7, 2021 . Professor Ruth Arnon has stepped down from her role as a member of VBL’s Board of Directors,
June 15, 2021
TEL AVIV, Israel , June 15, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today provided an update on its ongoing OVAL Phase 3 study investigating ofranergene obadenovec (VB-111), for the treatment of platinum-resistant ovarian cancer. The Company was notified by the U.S Food and Drug
June 3, 2021
Second primary endpoint added following discussion with the U.S. Food and Drug Administration Successfully meeting either PFS or OS primary endpoints expected to be sufficient for submitting a BLA   for potential full FDA approval PFS endpoint readout expected in 2022; BLA submission could be
Displaying 1 - 10 of 248